Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, Dalton WB, Christodoulou I, Paun BC, Varadhan R, Esteb C, Rajkhowa T, Bonifant C, Gondek LP, Levis MJ, Yegnasubramanian S, Ghiaur G, Jones RJ. Karantanos T, et al. Among authors: rajkhowa t. Haematologica. 2023 Jul 1;108(7):1886-1899. doi: 10.3324/haematol.2022.281444. Haematologica. 2023. PMID: 36519323 Free PMC article.
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.
Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, Helmenstine E, Rajkhowa T, Paun BC, Bonifant C, Dalton WB, Gondek LP, Moliterno AR, Levis MJ, Ghiaur G, Jones RJ. Karantanos T, et al. Among authors: rajkhowa t. Sci Adv. 2022 Feb 18;8(7):eabl8952. doi: 10.1126/sciadv.abl8952. Epub 2022 Feb 18. Sci Adv. 2022. PMID: 35179961 Free PMC article.
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Pratz KW, Kaplan J, Levy M, Bixby D, Burke PW, Erba H, Wise-Draper TM, Roboz GJ, Papadantonakis N, Rajkhowa T, Hernandez D, Dobler I, Gregory RC, Li C, Wang S, Stumpo K, Kannan K, Miao H, Levis M. Pratz KW, et al. Among authors: rajkhowa t. Haematologica. 2023 Mar 1;108(3):705-716. doi: 10.3324/haematol.2022.281216. Haematologica. 2023. PMID: 36226495 Free PMC article. Clinical Trial.
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M. Lee LY, et al. Among authors: rajkhowa t. Blood. 2017 Jan 12;129(2):257-260. doi: 10.1182/blood-2016-10-745133. Epub 2016 Dec 1. Blood. 2017. PMID: 27908881 Free PMC article. No abstract available.
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Strati P, et al. Among authors: rajkhowa t. Am J Hematol. 2015 Apr;90(4):276-81. doi: 10.1002/ajh.23924. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25530214 Free PMC article. Clinical Trial.
39 results